

AUTHOR CORRECTION

Open Access

Author Correction: Guangxi cobra venom-derived NGF promotes the osteogenic and therapeutic effects of porous BCP ceramic

Pan Jin^{1,2,3}, Fuqiang Yin⁴, Li Huang¹, Li Zheng^{1,2}, Jinmin Zhao^{1,2,3} and Xingdong Zhang⁵

Correction to: *Experimental & Molecular Medicine*
<https://doi.org/10.1038/emm.2016.173>
published online 7 April 2017

After online publication of this article, the authors noticed an error in the Figure section. The correct statement of this article should have read as below.

In the article cited above, incorrect figure was placed in Fig. 2c, d. The corrected image of Fig. 2 is printed below. Other parts of this article remain unchanged.

The authors apologize for any inconvenience caused.

Published online: 5 July 2019

Correspondence: Li Zheng (zhengli224@163.com) or
Jinmin Zhao (zhaojinmin@126.com)

¹Guangxi Engineering Center in Biomedical Materials for Tissue and Organ Regeneration, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China

²Guangxi Collaborative Innovation Center for Biomedicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China

³Guangxi Key Laboratory of Regenerative Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China

⁴The Medical and Scientific Research Center, Guangxi Medical University, Nanning, People's Republic of China

⁵National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, People's Republic of China

These authors contributed equally: Pan Jin, Fuqiang Yin.

© The Author(s) 2019



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.




Fig. 2 Concentration screening, cytotoxicity assay, FDA-PI staining, rhodamine phalloidin-Hoechst 33258 staining, alkaline phosphatase (ALP) activity assay, ALP staining, osteogenic-specific gene expression and Alizarin red staining of monolayer-cultured osteoblasts. **(A)** Screening of nerve growth factor (NGF) using various concentrations (0.625, 1.25, 2.5, 5, 7.8125, 10, 15.625, 20, 31.25, 62.5, 125 and 250 $\mu\text{g ml}^{-1}$) on 2D cultured osteoblasts using the MTT method after 3 days of treatment ($n = 3$). **(B)** Cytotoxicity assay with NGF at 0, 2.5, 5 and 10 $\mu\text{g ml}^{-1}$ on days 2, 5 and 8 ($n = 9$). **(C (a–d))** FDA-PI staining of osteoblasts treated with NGF at 0, 2.5, 5 and 10 $\mu\text{g ml}^{-1}$ after 8 days of treatment (Scale bar = 200 μm). **(C (e–h))** Rhodamine phalloidin-Hoechst 33258 staining of a monolayer culture treated with 0, 2.5, 5 and 10 $\mu\text{g ml}^{-1}$ NGF after 8 days (Scale bar = 100 μm). **(D)** ALP activity assay of osteoblasts treated with 0, 2.5, 5 and 10 $\mu\text{g ml}^{-1}$ NGF on days 2, 5 and 8 ($n = 9$). **(E (a–d))** ALP staining of osteoblasts treated with 0, 2.5, 5 and 10 $\mu\text{g ml}^{-1}$ NGF after 8 days (Scale bar = 500 μm). **(F (a–f))** Relative expression of bone morphogenetic protein-2 (*BMP2*, **F(a)**), runt-related transcription factor 2 (*RUNX2*, **F(b)**), alkaline phosphatase (*ALP*, **F(c)**), bone sialoprotein (*BSP*, **F(d)**), osteocalcin (*OCN*, **F(e)**) and alpha-1 type I collagen (*COL1A1*, **F(f)**) in osteoblasts treated with 0, 2.5, 5 and 10 $\mu\text{g ml}^{-1}$ NGF on days 2, 5 and 8 ($n = 3$). **(G (a–d))** Alizarin red staining of osteoblasts treated with 0, 2.5, 5 and 10 $\mu\text{g ml}^{-1}$ NGF after 8 days (Scale bar = 500 μm). The values are presented as the means \pm standard deviation. Bars with different letters at the same time point are significantly different from each other at $P < 0.05$, and bars with the same letter exhibit no significant difference